Skip to main content

Compare Stocks

Date Range: 

 BriaCell TherapeuticsSalvaRx GroupCotinga Pharmaceuticals Inc. (COT.V)Pacgen Life Science Co. (PBS.V)Motif Bio
SymbolNASDAQ:BCTXLON:SALVCVE:COTCVE:PBSLON:MTFB
Price Information
Current Price$3.16N/AC$0.04C$0.03N/A
52 Week RangeN/AN/AN/AN/AN/A
MarketRank™
Overall Score0.00.90.50.60.6
Analysis Score0.00.00.00.00.0
Community Score0.02.82.72.93.0
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.00.00.0
Earnings & Valuation Score0.01.90.00.00.0
Analyst Ratings
Consensus RecommendationN/AN/AN/AN/AN/A
Consensus Price TargetN/AN/AN/AN/AN/A
% Upside from Price TargetN/AN/AN/AN/AN/A
Trade Information
Market Cap$18.37 million£1.65 millionC$1.54 millionC$1.30 million£3.28 million
BetaN/AN/AN/AN/AN/A
Average Volume874,73150,75820,28163,60133,379,020
Sales & Book Value
Annual RevenueN/A£64.50 millionN/AC$302,079.00N/A
Price / SalesN/A0.00N/A6.44N/A
CashflowN/AN/AC$0.00 per shareC$0.00 per shareN/A
Price / CashN/A3.5017.5030.005.00
Book ValueN/AGBX 15.40 per shareC($0.18) per shareC$0.00 per shareGBX 0.10 per share
Price / BookN/A0.00N/A-30.00N/A
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSN/AGBX 168.80C($0.12)C($0.01)GBX (0.10)
Trailing P/E Ratio0.000.03N/AN/AN/A
Forward P/E RatioN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AC$0.24C$0.09N/A
Dividend YieldN/AN/A685.71%300.00%N/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/A N/A N/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A14.50%N/A78.48%N/A
Current RatioN/A1.89%0.05%0.81%4.39%
Quick RatioN/A1.89%0.01%0.40%3.36%
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
EmployeesN/A2N/AN/A6
Shares Outstanding5.81 million36.70 million21.99 million64.82 million654.99 million
Next Earnings Date7/5/2021 (Estimated)N/AN/AN/AN/A
OptionableNot OptionableNot OptionableOptionableNot OptionableNot Optionable
SourceHeadline
Motif Bio markets fundraising to accompany reverse takeover planMotif Bio markets fundraising to accompany reverse takeover plan
stockmarketwire.com - May 10 at 4:20 AM
Motif Bio PLC : Update re proposed Reverse TakeoverMotif Bio PLC : Update re proposed Reverse Takeover
markets.businessinsider.com - April 11 at 11:28 PM
Motif Bio progresses reverse takeover talksMotif Bio progresses reverse takeover talks
stockmarketwire.com - March 29 at 8:54 AM
Osteomyelitis Drugs Market potential growth, share, demand and analysis of key players – research forecasts to 2028Osteomyelitis Drugs Market potential growth, share, demand and analysis of key players – research forecasts to 2028
marketwatch.com - February 10 at 7:00 AM
Motif Bio progresses reverse takeover talks with healthcare companyMotif Bio progresses reverse takeover talks with healthcare company
stockmarketwire.com - January 27 at 7:48 AM
Motif Bio Plc Regulatory NewsMotif Bio Plc Regulatory News
lse.co.uk - January 5 at 9:33 AM
AstraZeneca shares rise as University of Oxford vaccine poised for UK approvalAstraZeneca shares rise as University of Oxford vaccine poised for UK approval
proactiveinvestors.co.uk - December 30 at 10:39 PM
MOTIF BIO PLC LS -,0001 (7MB.BE)MOTIF BIO PLC LS -,0001 (7MB.BE)
in.finance.yahoo.com - December 7 at 9:07 PM
Osteomyelitis Drugs Market 2020-2028 Research Report| Know The Growth Factors and Future ScopeOsteomyelitis Drugs Market 2020-2028 Research Report| Know The Growth Factors and Future Scope
marketwatch.com - December 6 at 12:58 PM
Motif Bio posts loss; in reverse takeover discussionsMotif Bio posts loss; in reverse takeover discussions
stockmarketwire.com - October 12 at 7:54 AM
Cash Shell Motif Bio Swings To Interim Loss On Derivative LiabilitiesCash Shell Motif Bio Swings To Interim Loss On Derivative Liabilities
lse.co.uk - October 12 at 7:54 AM
Motif Bio shares suspended from tradingMotif Bio shares suspended from trading
www.hl.co.uk - July 29 at 8:13 AM
Synairgen shows how to play soaring pricesSynairgen shows how to play soaring prices
www.investorschronicle.co.uk - July 22 at 1:34 PM
Delay in publication of Final ResultsDelay in publication of Final Results
www.sharecast.com - June 22 at 9:24 AM
Motif Bio Phase 3 Clinical Trial Finishes Patient Treatment PhaseMotif Bio Phase 3 Clinical Trial Finishes Patient Treatment Phase
www.bloomberg.com - June 10 at 7:32 PM
Motif Bio PLC, Spero Therapeutics, Inc. and Vical Incorporated Join Antimicrobials Working GroupMotif Bio PLC, Spero Therapeutics, Inc. and Vical Incorporated Join Antimicrobials Working Group
www.bloomberg.com - May 23 at 12:03 AM
Motif Bio raises £0.65m as it hunts for reverse takeover opportunityMotif Bio raises £0.65m as it hunts for reverse takeover opportunity
www.sharecast.com - May 5 at 6:47 AM
Aminex gets thumbs-up for salary sacrificesAminex gets thumbs-up for salary sacrifices
www.proactiveinvestors.co.uk - May 5 at 6:47 AM
Cash shell Motif Bio raises capital for balance sheet, working capitalCash shell Motif Bio raises capital for balance sheet, working capital
www.stockmarketwire.com - May 5 at 6:47 AM
Tern slides as losses more than doubleTern slides as losses more than double
www.proactiveinvestors.co.uk - May 5 at 6:47 AM
Brave Bisons new direction proving a hitBrave Bison's new direction proving a hit
www.proactiveinvestors.co.uk - May 4 at 3:45 PM
Motif Bio CEO Graham Lumsden stands down; becomes directorMotif Bio CEO Graham Lumsden stands down; becomes director
www.stockmarketwire.com - May 4 at 4:19 AM
Motif Bio says still no luck in finding a buyer for legacy assetsMotif Bio says still no luck in finding a buyer for legacy assets
www.proactiveinvestors.co.uk - March 18 at 7:42 AM
Motif Bio a step closer to cash shell status after agreement with its main lenderMotif Bio a step closer to cash shell status after agreement with its main lender
www.proactiveinvestors.co.uk - January 28 at 7:47 AM
Motif Bio Share ChatMotif Bio Share Chat
www.lse.co.uk - December 27 at 12:55 AM
DateCompanyBrokerageAction
12/11/2018SalvaRx GroupNorthland SecuritiesReiterated Rating
10/1/2019Motif BioPeel HuntReiterated Rating
(Data available from 5/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.